New England Journal of Medicine 2015-01-29

Perfecting breast-cancer treatment--incremental gains and musculoskeletal pains.

Dawn L Hershman

Index: N. Engl. J. Med. 372(5) , 477-8, (2015)

Full Text: HTML

Abstract

A fundamental feature of adjuvant therapy (treatment of apparently disease-free people to reduce the risk of recurrence) is that many are treated to benefit a few. The options for the adjuvant treatment of hormone-sensitive breast cancer have expanded in recent years. On the basis of meta-analyses of individual-patient data in studies dating back to 1985, tamoxifen has remained the standard of care in breast cancer. Tamoxifen reduces the annual rates of breast-cancer recurrence by almost half and mortality by one third. In absolute terms, this translates to 11.8 fewer recurrences and 9.2 fewer deaths per 100 women at 15 years. . . .

Related Compounds

  • Tamoxifen citrate
  • [D-Trp6]-LH-RH
  • Tamoxifen
  • Exemestane

Related Articles:

TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer.

2015-01-02

[Oncogene 34(1) , 27-38, (2015)]

Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.

2015-01-01

[Carcinogenesis 36(1) , 122-32, (2015)]

Exposure to the polyester PET precursor--terephthalic acid induces and perpetuates DNA damage-harboring non-malignant human breast cells.

2015-01-01

[Carcinogenesis 36(1) , 168-76, (2015)]

Chronic centrosome amplification without tumorigenesis.

2015-11-17

[Proc. Natl. Acad. Sci. U. S. A. 112 , E6321-30, (2015)]

Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats.

2014-12-01

[Toxicol. Pathol. 42(8) , 1188-96, (2014)]

More Articles...